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Background: The persistence of triptan use among newly prescribed users is low in the United States and
European countries. However, triptan refill patterns in Asian primary care practices have not been well described.
Methods: Data from the National Health Insurance Research Database in Taiwan were used to conduct a
retrospective cohort analysis from 2005 to 2008. All participants were followed for 2 years after receiving a new
triptan prescription. Refill and 2-year retention rates of newly prescribed triptans were calculated, and predictors of
the first triptan refill and 2-year retention were analyzed.
Results: Of the 13,951 participants with a new triptan prescription (99.9% sumatriptan), 67.4% were prescribed by a
neurologist, 67.4% were prescribed at least one prophylactic agent for migraine. Of them, 34.3% adhered to the
newly prescribed triptan at the first refill, 0.01% switched to another triptan, and 40.9% switched to a non-triptan
acute migraine medication. The 2-year retention rate was 4.0%. The frequency of headache-related neurologic visits
for 1 year before the index date, first prescription of triptan or other acute medications, first triptan prescription by
a neurologist, and prophylactic use were associated with higher first refill rates. The frequency of headache-related
neurologic visits 1 year before the index date and first triptan prescription by a neurologist were related to higher
2-year retention rates. Diabetes mellitus and first triptan prescription at a local medical clinic were associated with
reduced probability of continued triptan use at the first refill and 2 years.
Conclusions: Similar to Western societies, the refill and 2-year retention rates were low in new users of triptans.
Frequency of neurologic visits and triptan prescription by a neurologist were significant predictors of adherence.
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Migraine is a common, chronic, and disabling disorder of
neurovascular etiology, characterized by recurrent episodic
attacks and a variable presentation among patients. In
addition to its impact on the quality of life of afflicted
individuals, migraine imposes a substantial financial
burden on healthcare systems and employers [1]. The
prevalence of migraine in Taiwan is 9.1% among people
15 years and older, with a prevalence of 14.4% and 4.5% in
women and men, respectively [2]. Because many cases of
migraine are chronic and intermittent, it is recommended* Correspondence: sjwang@vghtpe.gov.tw
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in any medium, provided the original work is pthat patients undergo correct pharmacologic management
and retain the prescribed treatment to avert or relieve
debilitating pain, prevent escalation to acute medications,
and improve day-to-day functioning [3]. Although
preventive treatment can reduce disability by decreasing
the number and severity of attacks, many patients still
required acute abortive treatments [4].
The treatment of acute migraine is challenging because
of the high nonresponse rates to medications. Moreover, it
is difficult to predict individual response to a specific agent
or dose [5]. In the primary care setting, different panels
and guidelines recommend various medications [6-9].
Categories include nonspecific and specific treatments.
Nonspecific treatments are those effective for any pain
disorder and include non-steroidal anti-inflammatory drugs
(NSAIDs), combination analgesics, opioids, neuroleptics/
antiemetics, and corticosteroids. Specific therapies, suchOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and triptans, are effective only for migraine.
For many migraine patients, triptan therapy provides
complete pain relief of some attacks but not of others.
Triptan therapy is more likely to achieve complete pain
relief if administered early. In the United States and
European countries, triptans are recommended as a
first-line therapy for moderate-to-severe migraine [10,7].
According to the regulations for triptan use proposed by
the Taiwan National Health Insurance (NHI), triptans can
be prescribed only when the headache characteristics
fulfill the first edition of the diagnostic criteria of migraine
by the International Headache Society (1988) [11], and the
headache does not respond to other acute medications.
Only two kinds of triptans, sumatriptan and rizatriptan,
are available in Taiwan and have been provided to the
public by the NHI since 1999 and 2008, respectively. The
maximum recommended dosage per month of oral
sumatriptan is 400 mg, of intranasal sumatriptan is
four doses of 20 mg, and of oral rizatriptan is 40 mg.
Based on the 2009 National Ambulatory Care Survey
in the United States, over 80% of prescribed specific
antimigraine drugs were triptans. Of these, sumatriptan
accounted for almost half of all triptan prescriptions;
rizatriptan and eletriptan together accounted for about a
third [12]. Despite the widely reported efficacy and
tolerability of triptans, several studies showed that the
discontinuation of triptans was high [13-15]. According to
a US pharmacy claims database and European nationwide
practice databases, more than 50% of newly prescribed
triptan users never refilled their first triptan prescriptions
during a 2-year follow-up [16,17]. Moreover, only ~10% of
newly prescribed triptan users continued to use the same
triptan that was originally prescribed in a 2-year follow-up
period [16,17].
However, there have not been any reports regarding
adherence to, discontinuation of, and usage patterns
of migraine abortive medications in Asian countries. To
address this issue, we conducted a nationwide population-
based cohort study, with a similar design to those
conducted in the United States and Europe, to investigate
prescription refill patterns and predictors of adherence
among users of newly prescribed triptans, on the basis




A population-based retrospective cohort study was
performed with data from the Taiwan NHIRD. Since
1995, Taiwan’s National Health Insurance (NHI) program
has integrated all of the public insurance systems into a
single-payer program that provides comprehensive
healthcare to nearly 99% of the population in Taiwan.Through this system, patients can choose their preferred
physicians and health facilities, and they have the benefits
of comprehensive population coverage, short waiting
times, relatively low outpatient copayments, and use of
the NHIRD for planning, monitoring, and evaluating
healthcare services. However, the system has some
disadvantages, including short consultation time, poor
gate-keeping of specialist services, and lack of an effective
referral system.
The NHI Bureau established a program to construct the
NHIRD and to release claims data for academic and
medical research. According to the regulations established
by the Department of Health, patient identity is encrypted
for confidentiality and security. These databases allow
comprehensive utilization and provide enrollment
information, including demographic data, outpatient visit
records, hospitalization records, and drug prescription
registry information, for all patients. Diseases are coded
according to the 2001 International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).
The accuracy of the diagnoses listed in the NHIRD
has been validated previously for several diseases [18,19].
Study sample
The institutional review board of Taipei Veterans
General Hospital approved data collection efforts for this
study. We used a special dataset, which included all
migraine patients between 2004 and 2010 in Taiwan
according to the ICD-9-CM migraine diagnosis codes
(346.0×, 346.1×, and 346.9×). The total study population
in our study was 749,027 patients diagnosed with
migraine between Jan. 2005 and Dec. 2008. We identified
all migraine patients who were newly prescribed with
triptans between 2005 and 2008. The index date was
defined as the date of the first triptan prescription.
Patients had to be enrolled for a minimum of 12
months before the index triptan prescription and had
to undergo a 24-month observation period after the
index triptan prescription. The index triptans were
defined as the triptans newly prescribed at the index
date. Patients undergoing treatment with migraine
prophylactic agents, including amitriptyline, propranolol,
valproic acid, topiramate, and flunarizine, were to
continue treatment with at least one of these agents for at
least 28 days after the index date. We excluded subjects
who were prescribed triptans within 1 year before the
index date, were 20 years old or younger at the index date,
or had a follow-up period of less than 2 years. All patients
eligible for analysis were followed up for 2 years.
In Taiwan, three brands of triptans, i.e. index triptans,
were available during the study period: oral sumatriptan
(Imigran®, 50 mg), intranasal sumatriptan (Imigran Nasal
Spray®, 20 mg), and oral rizatriptan (Migoff ®, 10 mg).
Migraine-specific drugs were triptans and ergot alkaloids.
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as a prescription within the following four categories for a
patient with a migraine diagnostic code: NSAIDs, opioids,
salicylates, and acetaminophen.
Definitions
Patients enrolled in the index triptan population were
classified according to their refill patterns at the first
refill within 2 years after the index date. The following
categories were used for classification: (1) persistent users
(continued to refill the index triptan prescription), (2)
within-class switchers (switched from the index triptan to
another triptan), (3) between-class switchers (switched
from the index triptan to a non-triptan acute migraine
agent), and (4) discontinuers (no further prescription of
triptan or non-triptan acute migraine medications during
the 2-year follow-up period). Patients were defined as
having a “2-year retention of index triptan” when they
refilled at least one more prescription of the index triptan
within 90 days before the end of the 2-year follow-up
period.
Statistical analysis
Baseline demographic data included age, sex, income, and
urbanization. Urbanization levels in Taiwan are divided
into four strata according to the Taiwan National Health
Research Institute publications; Level 1 designates the
most urbanized areas, and level 4 designates the least
urbanized areas. The Charlson Comorbidity Index score
and cardiovascular disease risk equivalent were analyzed
to determine overall systemic health. During the 2-year
follow-up period, the overall numbers and percentages of
persistence, switching, and discontinuation of index
triptan were calculated. The probability of persistence at
each refill was computed by dividing the number of
patients with consecutive refills of the index triptan by the
total number of patients in the index population. The
probabilities of within- or between-class switches and
discontinuations, as well as the persistence rate of the
index triptan at the first refill within the 2-year follow-up
period were similarly calculated. Additionally, we calculated
the 2-year retention rate of the index triptan.
Univariate and multivariate, backward, conditional
Cox proportional hazard models were used to identify
the factors in association with continued use of triptans
at the first refill and at the end of the 2-year follow-up
period. Factors with a p-value < 0.1 in univariate analyses
were entered into the multivariate analyses. Microsoft
SQL Server 2012 (Microsoft Corp., Redmond, WA, USA)
was used for data linkage, processing, and sampling.
All statistical analyses were conducted with the STATA
statistical software program (version 12.0; StataCorp., Texas,
USA). A p-value < 0.05 was considered to be statistically
significant.Results
Characteristics of the study population
We identified 13,951 migraine patients who were newly
prescribed with triptans between January 2005 and
December 2008 and met the inclusion criteria. At the
index date, patients had a mean age of 41.3 years
(standard deviation, 13.7 years), and 77.0% of them
were women. 8.5% of the participants had cardiovascular
disease, 9.2% had diabetes mellitus, and 1.4% had peripheral
vascular disease. As the index prescription, 55.8% were pre-
scribed only one triptan, and 42.7% were prescribed one
triptan and other specific or non-specific acute migraine
medications. Only four patients were prescribed rizatriptan;
the remaining patients were prescribed sumatriptan
(99.9% of the cohort).
Overall, 9,397 patients (67.4%) were prescribed at least
one kind of migraine prophylactic agent, including pro-
pranolol (43.0%), flunarizine (30.8%), topiramate (23.2%),
valproic acid (6.3%), and amitriptyline (4.3%). Most triptans
were prescribed in the medical center (46.9%) and by
board-certified neurologists (67.4%). The detailed results
are shown in Table 1.
Triptan prescriptions during the 2-year follow-up period
At the first refill within the 2-year follow-up, 34.3% of
patients refilled their index triptan prescription at least
once (i.e., persistent users), 40.9% were between-class
switchers, and 0.01% were within-class switchers (i.e.,
switched to different triptans). Notably, 24.8% did not seek
any acute migraine treatment (i.e., discontinuers). Table 2
depicts the prescription patterns among between-class
switchers (n = 5,705) at the first refill. These users
filled prescriptions for NSAIDs (45.9%), acetaminophen
(45.7%), ergotamine (27.7%), opioids (3.0%), and salicylates
(2.1%). The rates of persistence, switching, and discontinu-
ation at each refill are presented in Table 3. After the
fourth refill, 10% or less of the index population remained
adherent to the index triptan. At 2 years after the index
date, only 4.0% of patients persistently used the index
triptan (i.e., rate of refill retention at 2 years = 4.0%).
Factors associated with persistent triptan use at the
first refill
Univariate analysis revealed an increased risk of adherence
to index triptans at the first refill in migraine patients with
age of 40 years or greater; residence in urbanization levels
2, 3, and 4; monthly income of NT$ 19,200 or greater; first
prescription by a neurologist; use of prophylactic agents;
or frequent ambulatory visits for headache. Risk of
adherence to triptans was reduced in patients with
diabetes mellitus, cerebrovascular diseases, or first
prescription at a local medical clinic (Table 4).
In multivariate analysis, increased frequency of neuro-
logic ambulatory visits for headache within 1 year before




No. of patient 13951
Female 10736 (77.0)
Age, mean (SD), years 41.3 (13.7)
Monthly income NT$
Dependent 2782 (19.9)
NT 0–19,200 3837 (27.5)
NT 19,200-42,000 5383 (38.6)
>NT42,000 1949 (14.0)
Urbanization
1 (Most urbanized) 6639 (47.6)
2 6528 (46.8)
3 6741 (4.8)
4 (Least urbanized) 110 (0.8)
Level of hospital
Level I (Medical center) 6548 (46.9)
Level II 4425 (31.7)
Level III 2066 (14.8)
Level IV (Local medical clinics) 912 (6.5)
Charlson comorbidity index score
Score 0 6521 (46.7)
Score 1 3787 (27.2)
Score 2 1849 (13.3)
Score ≥3 1794 (12.9)
Cardiovascular disease risk equivalent
Cerebrovascular disease 1187 (8.5)
Diabetes mellitus 1287 (9.2)
Peripheral vascular disease 201 (1.4)
Triptan prescription by a neurologist 9396 (67.4)
All ambulatory visits for any kind of disease within
one year before, median (IQR)
20 (11–35)
All ambulatory visits for headache within one year
before, median (IQR)
1 (0–5)
Neurologic ambulatory visits within one year before,
median (IQR)
0 (0–2)
Neurologic ambulatory visits for headache within
one year before, median (IQR)
0 (0–1)
Triptan only 7784 (55.8)
Triptan plus other acute medications 6167 (44.2)
Sumatriptan, oral 13841 (99.2)
Sumatriptan, nasal 105 (0.75)




Table 1 Baseline characteristics of patients using triptans
(2005–2008) (Continued)
Propranolol 5995 (43.0)
Valproic acid 884 (6.3)
Topiramate 3237 (23.2)
Flunarizine 4294 (30.8)
At least one prophylactic agent 9397(67.4)
1 US dollar = 29.9 New Taiwan Dollar (NT) on 1/1/2014.
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gist, first prescription of triptan and other acute medica-
tions, and use of at least one migraine prophylactic
agent were associated with a significantly increased
probability of continuing index triptan use at the time
of the first refill. In contrast, diabetes mellitus and
first prescription of triptan in a local medical clinic
were significantly associated with a reduced probability of
continuing use of the index triptan at the time of the first
refill (Table 4).Factors associated with persistent triptan use at 2 years
Univariate analysis revealed an increased risk of adher-
ence to index triptans at 2 years in migraine patients
with a monthly income of NT$ 42,000 or greater, first
prescription by a neurologist, or increased frequency of
neurologic ambulatory visits for headache. In contrast,
patients with diabetes mellitus or first prescription at a
local medical clinic had a reduced risk of adherence
(Table 5).
In multivariate analysis, increased frequency of neuro-
logic ambulatory visits for headache within 1 year before
the index date and first prescriptions of triptan by a
neurologist were associated with a significantly increased
probability of continuing index triptan use at 2 years.
Diabetes mellitus and first prescription of triptan at a
local medical clinic were significantly associated with
a reduced probability of continuing index triptan use
at 2 years (Table 5).Discussion
The results of our nationwide cohort study demonstrate
that most first-time triptan users are females aged 30–50
years and prescribed triptans by a neurologist. The index
triptan prescriptions were refilled by 34.3% of patients,
whereas about 40% switched to non-triptan acute mi-
graine agents at the first refill. Due to limited avail-
ability of different triptans in Taiwan, only 0.01%
refilled their prescriptions with an alternative triptan.
Overall, the rate of refilling triptans decreased mark-
edly after the first refill. At the end of the 2-year
follow-up period, only 4.0% maintained their index
triptan.
Table 2 Prescription patterns among between-class
switchers at the first refill
N (%)






Opioids and salicylates 2 0.04
Opioids and NSAIDs 13 0.27
Opioids and ergotamine 43 0.75
Abbreviations: NSAIDs non-steroidal anti-inflammatory drugs.
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Table 6 compares triptan refill patterns at the first refill
and after 2 years among five cohorts (i.e., for this study
and in the United States and Europe). We adopted a
similar methodology to those applied in retrospective
cohort studies of a pharmacy claims database in the
United States and nationwide practice databases in
Europe [16,17].
Among the five cohorts, at the time of the first
refill, 25–45% of triptan users continued the index
triptan, 53–66% discontinued the index triptan, and
25–55% stopped all acute migraine medications [16,17].
Approximately 5–7% of US and European triptan users
switched to alternative triptans, compared to only 0.01%
in Taiwan. The proportion of between-class switchers was
higher in Taiwan and the United States than in Europe
[17,16]. Most between-class switchers in the United
States switched to opioids or barbiturates, whereas







1st refill 4787 1 5705 3458
2nd refill 2775 0 1206 807
3rd refill 1922 0 477 376
4th refill 1457 0 279 186
5th refill 1148 0 181 128
6th refill 916 0 128 104
7th refill 780 0 63 73
8th refill 648 0 44 88
9th refill 540 0 43 65
10th refill 453 0 20 67
11th refill 396 0 15 42
At 2 years 13951 1 8161 5394in Taiwan [16,17]. At the end of the 2-year follow-up
period, only 4–13% retained their index triptan
[16,17].
Although the refill pattern was similar among dif-
ferent countries, there were discrepancies related to
the accessibility of abortive medications in the differ-
ent healthcare systems. The accessibility of triptans is
limited in Taiwan, and barbiturates are not available
in Taiwan or Europe. Unlike many Western countries,
after implementation of the NHI in Taiwan, the med-
ical treatment-seeking behavior of patients changed
because of freedom to select any healthcare provider
or hospital based on preference without referral; on
average, a person had 15.1 physician consultations per
year in 2013 [20]. In Taiwan, triptans can be pre-
scribed by a neurologist or primary care physician, as
long as the indication fulfills the regulations recom-
mended by the NHI.
Factors associated with persistence and discontinuation
Patients with higher frequencies of clinic visits for
headache before the index date might have experienced
more severe headaches, which could have precluded
their premature termination of treatment. In a previous
study, patients reported fewer side effects of triptans
with increasing age and patients who tolerated triptans
better were more likely to continue triptans [21].
Prescription by a neurologist was a contributing factor
for sustained triptan use. Patients who visit a specialist
may be more confident in their prescriber or receive
more detailed information about triptan use [22].
Confidence in specialists and satisfaction with the ability
of triptans to eliminate migraine and restore normal
functioning are important predictors of adherence to








34.31 0.01 40.89 24.79
19.89 0 8.64 5.78
13.78 0 3.42 2.70
10.44 0 2.00 1.33
8.23 0 1.30 0.92
6.57 0 0.92 0.75
5.59 0 0.45 0.52
4.64 0 0.32 0.63
3.87 0 0.31 0.47
3.25 0 0.14 0.48
2.84 0 0.11 0.30
4.00 0.01 58.50 38.7
Table 4 Factors associated with continuing using index triptan at first refill
Univariate Multivariate
Variable Odds ratio (95 CI) p value Odds ratio (95 CI) p value
Age
20-40 1
≥40 0.88 (0.82-0.94) <0.001
Male 0.97 (0.89-1.05) 0.461
Urbanization
Level 1 (Most urbanized) 1
Level 2 0.91 (0.85-0.98) 0.012
Level 3 0.77 (0.65-0.92) 0.003
Level 4 (Least urbanized) 0.70 (0.47-1.06) 0.096
Monthly income (NT$)
Dependent 1
NT$ 0–19,200 1.05 (0.94-1.16) 0.377
NT$ 19,200-42,000 1.16 (1.05-1.28) 0.003
>NT$ 42,000 1.46 (1.29-1.64) <0.001
Diabetes mellitus 0.62 (0.54-0.71) <0.001 0.75 (0.65-0.87) <0.001
Cerebrovascular diseases 0.77 (0.68-0.88) <0.001
Peripheral vascular disease 0.79 (0.58-1.08) 0.136
Frequency of ambulatory visit for headache within one year before index date 1.02 (1.02-1.03) <0.001 1.01 (1.00-1.02) 0.012
Neurologic ambulatory visit for headache within one year before index date 1.09 (1.08-1.11) <0.001 1.05 (1.04-1.07) <0.001
First prescription including triptan and other acute medications 1.35 (1.26-1.45) <0.001 1.09 (1.01-1.17) <0.001
First prescription of triptan by neurologists 3.45 (3.17-3.77) <0.001 3.08 (2.81-3.37) <0.001
Use of at least one prophylactic agent* 1.46 (1.35-1.58) <0.001 1.37 (1.27-1.49) <0.001
Hospital level of first prescription of triptan
Level I (Medical center) 1 1
Level II 0.95 (0.87-1.03) 0.205 0.97(0.89-1.06) 0.494
Level III 0.98 (0.88-1.09) 0.719 1.02 (0.91-1.14) 0.717
Level IV (Local medical clinics) 0.79 (0.68-0.92) 0.002 0.74 (0.63-0.87) <0.001
*Prophylactic agents include amitriptyline, propranolol, valproic acid, topiramate and flunarizine.
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usually increased when combined with prophylactic
drugs [24].
Triptan discontinuation has been associated with
concomitant narcotic use, medication overuse, and
higher Migraine Disability Assessment Test or Beck
Depression Inventory scores [25,22]. When selecting
an oral triptan, migraine sufferers and primary care
physicians consider triptan effectiveness more important
than tolerability of side effects or consistency of triptan
effects [26]. Moreover, the patient’s desire to play an
active role as a decision-maker should not be overlooked
and insight is needed into individual needs and whether
expectations are being fulfilled [27].
Considering the side effects, drug interactions, and
contraindications of triptans, it may be that medical
comorbidities, especially diseases with cardiovasculardisease risk, influence the adherence to triptans. Migraine
patients with diabetes mellitus tended to discontinue
triptan, although we cannot provide valid explanations for
this phenomenon. The other significant factor associated
with triptan discontinuation was triptan prescription by a
physician at a local clinic or community hospital. This
result can be attributed to the fact that patients in Taiwan
are less confident in the medical services provided at local
medical institutes.
Reasons for low percentage and frequency of triptan use
In an earlier study, migraine patients tended to discontinue
triptans immediately after the index date [16]. Potential
reasons for low triptan refills may include the side effects
of triptans, lack of efficacy, uncertain diagnosis of
headache, and diminished headache frequency or headache
improvement.
Table 5 Factors associated with retention refill of index triptan at 2 years
Univariate Multivariate
Variable Odds ratio (95 CI) p value Odds ratio (95 CI) p value
Age
20-40 1
≥40 1.06 (0.89-1.26) 0.509
Male 1.15 (0.94-1.39) 0.170
Urbanization
Level 1 (Most urbanized) 1
Level 2 0.93 (0.78-1.11) 0.425
Level 3 0.63 (0.39-1.02) 0.061
Level 4 (Least urbanized) 1.05 (0.43-2.60) 0.909
Monthly income (NT$)
Dependent 1
NT$ 0–19,200 0.80 (0.61-1.07) 0.131
NT$ 19,200-42,000 1.22 (0.96-1.56) 0.108
>NT$ 42,000 2.12 (1.62-2.77) <0.001
Diabetes mellitus 0.47 (0.32-0.71) <0.001 0.59 (0.39-0.89) 0.011
Cerebrovascular diseases 0.74 (0.52-1.04) 0.085
Peripheral vascular disease 0.87 (0.41-1.86) 0.721
Frequency of ambulatory visit for headache within one year before index date 0.99 (0.99-1.01) 0.892
Neurologic ambulatory visit for headache within one year before index date 1.04 (1.02-1.07) 0.001 1.05 (1.02-1.07) 0.002
First prescription including triptans and other acute medications 1.07 (0.90-1.27) 0.427
First prescription of triptan by neurologists 3.02 (2.37-3.84) <0.001 2.70 (2.12-3.45) <0.001
Use of at least one prophylactic agent* 1.03 (0.86-1.24) 0.722
Hospital level of first prescription of triptan
Level I (Medical center) 1 1
Level II 0.71 (0.58-0.86) 0.001 0.74 (0.60-0.90) 0.003
Level III 0.86 (0.68-1.11) 0.247 0.91 (0.71-1.17) 0.476
Level IV (Local medical clinics) 0.36 (0.22-0.61) <0.001 0.34 (0.20-0.58) <0.001
*Prophylactic agents include amitriptyline, propranolol, valproic acid, topiramate and flunarizine.
Table 6 Refill patterns at the first refill and 2-year
retention, % of total cohort
Taiwan US UK France Germany
Persistent users 34.3 25.5 44.3 34.2 36.7
Within-class switchers 0.01 7.4 4.9 6.8 6.3
Between-class switchers 40.9 67.1 2.3 4.0 2.3
Opioids 1.2 18.2 0.1 0 0
NSAIDs 18.8 12.5 0.9 2.0 1.3
Barbiturates 0 2.6 0 0 0
Ergot derivatives 11.3 0 0.2 0.6 0.1
Discontinuers 24.8 25.5 48.5 54.9 54.7
2-year retention rate 4.0 6.4 13.0 6.0 9.0
Abbreviations: NSAIDs non-steroidal anti-inflammatory drugs.
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solo practice, never prescribe triptans for migraine
because of their high cost [28]. Concurrent use of
non-triptan medications was fairly common in sustained
triptan users to abort acute migraine attacks [16].
Prescription data reveal a very low percentage (0.4–1.4%
of the general population) of triptan use in several
countries; this circumstance was common and universal
among migraine patients [29-31].
More than 30% of patients and up to 40% of migraine
attacks fail to respond to a particular triptan, either because
of suboptimal efficacy or tolerability issues [32]. Although
patients who respond poorly to one triptan may respond
better to another, most patients discontinue triptan treat-
ment without trying another kind [33]. For many patients,
satisfactory responses to over-the-counter (OTC) drugs and
NSAIDs, as well as concomitant use of prophylactic agents,
Chen et al. The Journal of Headache and Pain 2014, 15:48 Page 8 of 9
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prescription of triptans.
Conclusion
The tendency to discontinue triptan treatment after the
initial prescription among migraine patients appears to
be a universal finding across countries. Reasons for
triptan non-adherence and relationships among demo-
graphic, psychological, and behavioral correlates and
triptan adherence warrant further investigation.
Potential study limitations
The data analyzed in our cohort study were obtained
from the NHIRD of Taiwan. The NHIRD only records
NHI-covered medical system usage. Therefore, data
regarding the use of drugs not covered by the NHI, such
as OTC drugs, were not available for study. Although
these disadvantages should be accounted for or mini-
mized through the study design, the NHIRD can be con-
sidered as a powerful tool for pharmaco-epidemiology
studies. Lack of information on adverse events in the
database makes it impossible to analyze the relationship
between adherence/persistence and triptan tolerability.
Because of the different healthcare systems adopted by
Taiwan, the United States, and European countries, as
well as the inherent limitations associated with the data-
base study design, direct comparisons of the persistence
and refill patterns of triptans should be interpreted with
caution.
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